Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway.
Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway.
复制标题
多发性骨髓瘤通过诱导戊糖磷酸途径获得对 EGFR 抑制剂的耐药性
DOI:
10.1038/srep09925
复制
发表时间:
2015-04-20
影响因子:
4.6
通讯作者:
Chen G
中科院分区:
文献类型:
--
作者:
Chen Y;Huang R;Ding J;Ji D;Song B;Yuan L;Chang H;Chen G
Multiple myeloma (MM) was characterized by frequent mutations in KRAS/NRAS/BRAF within the EGFR pathway that could induce resistance to EGFR inhibitors. We here report that EGFR inhibition solely exhibited moderate inhibition in KRAS/NRAS/BRAF wildtype (triple-WT) MM cells, whilst had no effect in myeloma cells with any of the mutated genes. The moderate inhibitory effect was conferred by induction of pentose phosphate pathway (PPP) when cells were treated with Gefitinib, the EGFR inhibitor. Combination of Gefitinib with PPP inhibitor 6AN effected synergistically in triple-WT cells. The inhibition could be restored by addition of NADPH. Dual EGFR/ERBB2 inhibitor Afatinib also exhibited similar effects. Further genetic silencing of EGFR, ERBB2 and mTOR indicated that major effect conferred by ERBB2 was via convergence to EGFR pathway in MM. Our results contributed to the individualized targeted therapy with EGFR inhibitors in MM.
登录
查看更多内容
影响因子:
20.3
作者:
Liu, PC;Leong, T;VanNess, B
通讯作者:
VanNess, B
影响因子:
45.3
作者:
Decaux, Olivier;Lode, Laurence;Minvielle, Stephane
通讯作者:
Minvielle, Stephane
影响因子:
--
作者:
Stincone A;Prigione A;Cramer T;Wamelink MM;Campbell K;Cheung E;Olin-Sandoval V;Grüning NM;Krüger A;Tauqeer Alam M;Keller MA;Breitenbach M;Brindle KM;Rabinowitz JD;Ralser M
通讯作者:
Ralser M
影响因子:
64.8
作者:
通讯作者:
--
影响因子:
3.5
作者:
Hothersall, JS;Gordge, M;Noronha-Dutra, AA
通讯作者:
Noronha-Dutra, AA